Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Clin Oncol ; 16(4): 93, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35350405

RESUMEN

Klotho, a cellular anti-senescence protein, is related to antitumor actions, growth regulation, proliferation and invasiveness in several types of tumor, including breast cancer. The present study aimed to analyze the serum levels of αKlotho in patients with breast cancer according to histopathological and immunohistochemical variables. A total of 74 patients and 60 healthy controls were recruited. Peripheral blood samples were collected and serum levels were assessed by sandwich ELISA. Clinical and diagnostic data were obtained from medical records and databases of the Clinical Hospital of the Federal University of Uberlândia (Uberlândia, Brazil). The results indicated no difference in the levels of αKlotho between patients and controls (P=0.068); however, the number of patients with breast cancer with undetectable αKlotho was high (n=52). Thus, the variables that were associated with the lowest survival rates were analyzed, relating them to undetectable αKlotho. Among cases of metastatic tumors or tumors with poor differentiation, positive lymph node status and triple-negative status, patients with undetectable αKlotho predominated and had unfavorable overall survival. Due to the significant results obtained in triple-negative patients, an in vitro analysis was performed to determine whether estrogen receptors (ERs) have a role in αKlotho production. Treatment of MCF-7 cells with ER agonists, estradiol (E2) and diarylpropionitrile (DPN), resulted in increases in αKlotho expression and supernatant levels of both agonists, demonstrating a direct association between the ER and Klotho production; of note, the ERß-specific agonist DPN tripled αKlotho expression when compared to E2 (P=0.078). These data suggested that undetectable αKlotho in the serum of patients with breast cancer is related to unfavorable histopathological variables and poor prognosis and ERs possibly have an important role in maintaining adequate quantities of αKlotho.

2.
Surg Oncol ; 38: 101596, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34015750

RESUMEN

INTRODUCTION: Oncological surgery must follow some fundamental principles to be truly curative, one of which is the resection of the tumor with surgical margins free of neoplasia. In breast cancer, surgery with positive margins should be expanded immediately. There are probably different intensities, between the stages and molecular subtypes of operable breast cancer, of worsening prognosis due to the surgical margin compromised by the neoplasia in women not submitted to the necessary enlargement of the positive surgical margin. MATERIALS AND. METHODS: Seven hundred and forty-seven women with invasive ductal carcinoma of the breast, analyzing anatomical-pathological information, types of surgery, molecular subtypes, and the presence or absence of the surgical margin compromised by neoplasia. RESULTS: Sixty-one (8.2%) patients had positive surgical margin, causing 2.85 times more risk of locoregional relapse compared to negative surgical margin by multivariate analysis. In subgroup analysis, among stages I, II and III, stage II was the most negatively impacted, with those patients presenting 2.42 times more risk of distant metastasis and 4.94 times more risk of locoregional relapses compared to negative surgical margin by multivariate analysis. Among the molecular subtypes, Triple Negative tumors with a positive surgical margin had 3.56 times more risk of death, 4.98 times more risk of distant metastasis and 5.55 times more risk of locoregional relapse compared to negative surgical margin by multivariate analysis. CONCLUSIONS: The positive surgical margin, especially in Stage II and Triple-Negative breast cancer patients negatively impact the patient's evolution, increasing risk of distant metastasis and death.


Asunto(s)
Márgenes de Escisión , Mastectomía/mortalidad , Recurrencia Local de Neoplasia/cirugía , Neoplasias de la Mama Triple Negativas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Estudios Retrospectivos , Tasa de Supervivencia , Neoplasias de la Mama Triple Negativas/patología
3.
Biochem Biophys Res Commun ; 533(4): 1021-1026, 2020 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-33012510

RESUMEN

Recently, a high number of copper derivatives has been evaluated as DNA-targeting metallodrugs, due to the lower toxicity and its potential to cleave DNA. Several strategies have been testing to develop metal compounds effective against tumour cells. In this work, the ternary copper (doxycycline)-(1,10-phenanthroline) complex [Cu(dox)(phen)]2+ was especially designed as an antitumoral drug, previously showing high cytotoxicity and DNA cleavage activity. We aimed to further investigate the in vitro cytotoxic activity in both tumoral and non-tumoral cells, in vitro genotoxic potential, and in vivo antitumor activity using BALB/C mouse injected with sarcoma S180 and Ehrlich cell lines. Our results indicated that this compound exhibits a moderate genotoxic potential, with selective growth inhibition of tumor cells, especially the murine melanoma B16F10. Its main mechanism of action seems to be through ROS generation. We have further shown a significant reduction of the implanted tumor size in the animal model, suggesting that this compound has great antitumoral potential against many tumor types. [Cu(dox)(phen)]2+ is selectively cytotoxic for melanoma B16F10 and showed high chemotherapeutic potential in vivo against implanted sarcoma S180 and Ehrlich ascites tumours.


Asunto(s)
Antineoplásicos/farmacología , Cobre/farmacología , Compuestos Organometálicos/farmacología , Animales , Carcinoma de Ehrlich/tratamiento farmacológico , Carcinoma de Ehrlich/metabolismo , Carcinoma de Ehrlich/patología , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Daño del ADN , Doxiciclina/análogos & derivados , Doxiciclina/farmacología , Diseño de Fármacos , Ensayos de Selección de Medicamentos Antitumorales , Técnicas In Vitro , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Ratones , Ratones Endogámicos BALB C , Células RAW 264.7 , Sarcoma 180/tratamiento farmacológico , Sarcoma 180/metabolismo , Sarcoma 180/patología , Tetraciclinas/farmacología
4.
Immunobiology ; 225(3): 151904, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31959539

RESUMEN

B cells contribute to the immune system in many ways such as antigen presentation to CD4+ T cells, secretion of cytokines and lymphoid tissue organogenesis. Furthermore, they are the only cell type capable of producing immunoglobulins. B cells also account for critical aspects of the resistance against intracellular pathogens. Trypanosoma cruzi is an intracellular parasite that sabotages humoral response by depletion of immature B cells. Polyclonal activation and secretion of non-specific antibodies are also other mechanisms used by T cruzi to evade and subvert the mammalian host immune system, leading to increased parasitemia and susceptibility to Chagas' disease. It remained unclear whether B cell depletion occurs due to direct contact with T. cruzi or results from a global increase in inflammation. Unlike previous reports, we demonstrated in this study that T. cruzi infects human B cells, resulting in parasite-induced activation of caspase-7 followed by proteolytic cleavage of phospholipase Cγ1 and cell death. These data contribute to explain the mechanisms ruling B-cell depletion and evasion of the immune response by T. cruzi.


Asunto(s)
Actinas/metabolismo , Linfocitos B/inmunología , Linfocitos B/metabolismo , Caspasa 7/metabolismo , Interacciones Huésped-Patógeno , Fosfolipasa C gamma/metabolismo , Trypanosoma cruzi/inmunología , Muerte Celular , Enfermedad de Chagas/inmunología , Enfermedad de Chagas/metabolismo , Enfermedad de Chagas/parasitología , Humanos , Proteolisis
5.
Chembiochem ; 20(18): 2390-2401, 2019 09 16.
Artículo en Inglés | MEDLINE | ID: mdl-31026110

RESUMEN

Class 1 myosins (Myo1s) were the first unconventional myosins identified and humans have eight known Myo1 isoforms. The Myo1 family is involved in the regulation of gene expression, cytoskeletal rearrangements, delivery of proteins to the cell surface, cell migration and spreading. Thus, the important role of Myo1s in different biological processes is evident. In this study, we have investigated the effects of pentachloropseudilin (PClP), a reversible and allosteric potent inhibitor of Myo1s, on angiogenesis. We demonstrated that treatment of cells with PClP promoted a decrease in the number of vessels. The observed inhibition of angiogenesis is likely to be related to the inhibition of cell proliferation, migration and adhesion, as well as to alteration of the actin cytoskeleton pattern, as shown on a PClP-treated HUVEC cell line. Moreover, we also demonstrated that PClP treatment partially prevented the delivery of integrins to the plasma membrane. Finally, we showed that PClP caused DNA strand breaks, which are probably repaired during the cell cycle arrest in the G1 phase. Taken together, our results suggest that Myo1s participate directly in the angiogenesis process.


Asunto(s)
Citoesqueleto de Actina/efectos de los fármacos , Inhibidores de la Angiogénesis/farmacología , Ciclo Celular/efectos de los fármacos , Hidrocarburos Clorados/farmacología , Integrinas/metabolismo , Pirroles/farmacología , Inhibidores de la Angiogénesis/toxicidad , Adhesión Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana , Humanos , Hidrocarburos Clorados/toxicidad , Integrinas/genética , Miosina Tipo I/metabolismo , Pirroles/toxicidad , ARN Mensajero/metabolismo
6.
Artículo en Inglés | MEDLINE | ID: mdl-18442739

RESUMEN

OBJECTIVE: The objective of this study was to determine the effect of MTA on the expression of cytokines in mouse pulp tissue. STUDY DESIGN: Pulp tissue was exposed to MTA, and the expression of CCL5/RANTES, CCL2/MCP1, IL-1alpha, IFN-gamma, TNF-alpha, IL-4, and IL-6 was evaluated by RT-PCR at 10 and 20 days after exposure. Control groups were not exposed to MTA. RESULTS: We found no detectable expression of CCL2, IL-4, and IL-6 in the tissue from either group, while TNF-alpha was expressed at high levels 20 days after exposure (P < .05). CCL5 and IL-1alpha mRNA expression was lower in the MTA-treated group 10 days after treatment (P < .05). At 20 days after the surgical procedure, IFN-gamma mRNA expression was also lower in the MTA-treated group (P < .05). CONCLUSIONS: These findings suggest that MTA down-regulates the inflammatory cytokines CCL5, IL-1alpha and IFN-gamma and may have an anti-inflammatory effect.


Asunto(s)
Compuestos de Aluminio/farmacología , Compuestos de Calcio/farmacología , Citocinas/biosíntesis , Pulpa Dental/efectos de los fármacos , Óxidos/farmacología , Pulpotomía/métodos , Materiales de Obturación del Conducto Radicular/farmacología , Silicatos/farmacología , Animales , Quimiocina CCL5/biosíntesis , Pulpa Dental/metabolismo , Recubrimiento de la Pulpa Dental/métodos , Regulación hacia Abajo , Combinación de Medicamentos , Expresión Génica , Mediadores de Inflamación/metabolismo , Interferón gamma/biosíntesis , Interleucina-1/biosíntesis , Ratones , Ratones Endogámicos C57BL , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Necrosis Tumoral alfa/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...